Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling

Nature

Volumn 497, Issue 7451, 2013, Pages 638-642

  Zimmermann, Gunther ^a   Papke, Björn ^a   Ismail, Shehab ^a   Vartak, Nachiket ^a   Chandra, Anchal ^a   Hoffmann, Maike ^b   Hahn, Stephan A ^b   Triola, Gemma ^a   Wittinghofer, Alfred ^a   Bastiaens, Philippe I H ^a,c   Waldmann, Herbert ^a,c  

^a MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c TU DORTMUND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BINDING PROTEIN; DELTARASIN; K RAS PROTEIN; UNCLASSIFIED DRUG;

CANCER; CYTOPLASM; DRUG DEVELOPMENT; INHIBITION; MOLECULAR ANALYSIS; PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CANCER CELL; CELL PROLIFERATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SCREENING;

ADENOCARCINOMA; ANIMALS; BENZIMIDAZOLES; BINDING SITES; CARCINOMA, PANCREATIC DUCTAL; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 6; DOGS; HUMANS; HYDROGEN BONDING; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NEOPLASM TRANSPLANTATION; ONCOGENE PROTEIN P21(RAS); PROTEIN BINDING; SIGNAL TRANSDUCTION;

MAMMALIA;

EID: 84878401236     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature12205     Document Type: Article

References (26)

1. Malumbres, M. & Barbacid, M. RAS oncogenes: the first 30 years. Nature Rev. Cancer 3, 459-465 (2003).
2. Gelb, M. H. et al. Therapeutic intervention based on protein prenylation and associated modifications. Nature Chem. Biol. 2, 518-528 (2006).
3. Downward, J. Targeting RAS signalling pathways in cancer therapy. Nature Rev. Cancer 3, 11-22 (2003).
4. Berndt, N., Hamilton, A. D. & Sebti, S. M. Targeting protein prenylation for cancer therapy. Nature Rev. Cancer 11, 775-791 (2011).
5. Roberts, P. J. & Der, C. J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26, 3291-3310 (2007).
6. Maurer, T. et al.Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc. Natl Acad. Sci. USA 109, 5299-5304 (2012).
7. Patgiri, A., Yadav, K. K., Arora, P. S.&Bar-Sagi, D. An orthosteric inhibitor of the Ras-Sos interaction. Nature Chem. Biol. 7, 585-587 (2011).
8. Sun, Q. et al. Discovery of small molecules that bind to K-Ras and inhibit Sosmediated activation. Angew. Chem. Int. Edn 51, 6140-6143 (2012).
9. Chandra,A. et al. TheGDI-like solubilizing factorPDEd sustains the spatial organization and signalling of Ras family proteins. Nature Cell Biol. 14, 329-329 (2012).
10. Ismail, S. A. et al. Arl2-GTP and Arl3-GTP regulate a GDI-like transport system for farnesylated cargo. Nature Chem. Biol. 7, 942-949 (2011).
11. Zhang, H. et al. Photoreceptor cGMP phosphodiesterase d subunit (PDEd) functions as a prenyl-binding protein. J. Biol. Chem. 279, 407-413 (2004).
12. Chen, Y. X. et al. Synthesis of the Rheb and K-Ras4B GTPases. Angew. Chem. Int. Edn 49, 6090-6095 (2010).
13. Chidley, C., Haruki, H., Pedersen, M. G., Muller, E. & Johnsson, K. A yeast-based screen reveals that sulfasalazine inhibits tetrahydrobiopterin biosynthesis. Nature Chem. Biol. 7, 375-383 (2011).
14. Vedadi, M. et al. Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination. Proc. Natl Acad. Sci. USA 103, 15835-15840 (2006).
15. Monovich, L. G. et al. Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13. J. Med. Chem. 52, 3523-3538 (2009).
16. Wright, K. J. et al. An ARL3-UNC119-RP2 GTPase cycle targets myristoylated NPHP3 to the primary cilium. Genes Dev. 25, 2347-2360 (2011).
17. Zhang, H. et al. UNC119 is required for G protein trafficking in sensory neurons. Nature Neurosci. 14, 874-880 (2011).
18. Elad-Sfadia, G., Haklai, R., Balan, E. & Kloog, Y. Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity. J. Biol. Chem. 279, 34922-34930 (2004).
19. Paz, A., Haklai, R., Elad-Sfadia, G., Ballan, E. & Kloog, Y. Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene 20, 7486-7493 (2001).
20. Bhagatji, P., Leventis, R., Rich, R., Lin, C. J. & Silvius, J. R. Multiple cellular proteins modulate the dynamics of K-ras associationwith the plasmamembrane. Biophys. J. 99, 3327-3335 (2010).
21. Wouters, F. S., Verveer, P. J. & Bastiaens, P. I. H. Imaging biochemistry inside cells. Trends Cell Biol. 11, 203-211 (2001).
22. Grecco, H. E. et al. In situ analysis of tyrosine phosphorylation networks by FLIM on cell arrays. Nature Methods 7, 467-472 (2010).
23. Grecco, H. E., Roda-Navarro, P. & Verveer, P. J. Global analysis of time correlated single photon counting FRET-FLIM data. Opt. Express 17, 6493-6508 (2009).
24. Moore, P. S. et al. Genetic profile of 22 pancreatic carcinoma cell lines. Virchows Arch. 439, 798-802 (2001).
25. Berrozpe, G., Schaeffer, J., Peinado, M. A., Real, F. X. & Perucho, M. Comparativeanalysis ofmutations in the p53 and K-ras genes in pancreatic-cancer. Int. J. Cancer 58, 185-191 (1994).
26. Perez-Tomas, R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr. Med. Chem. 13, 1859-1876 (2006).